[go: up one dir, main page]

WO2012078121A3 - Forme posologique orale solide comprenant cefdinir - Google Patents

Forme posologique orale solide comprenant cefdinir Download PDF

Info

Publication number
WO2012078121A3
WO2012078121A3 PCT/TR2011/000273 TR2011000273W WO2012078121A3 WO 2012078121 A3 WO2012078121 A3 WO 2012078121A3 TR 2011000273 W TR2011000273 W TR 2011000273W WO 2012078121 A3 WO2012078121 A3 WO 2012078121A3
Authority
WO
WIPO (PCT)
Prior art keywords
cefdinir
dosage form
oral dosage
solid oral
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000273
Other languages
English (en)
Other versions
WO2012078121A2 (fr
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012078121A2 publication Critical patent/WO2012078121A2/fr
Publication of WO2012078121A3 publication Critical patent/WO2012078121A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant cefdinir comme agent actif, et une méthode de production destinée à la préparation de ces compositions.
PCT/TR2011/000273 2010-12-08 2011-12-02 Forme posologique orale solide comprenant cefdinir Ceased WO2012078121A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/10212A TR201010212A2 (tr) 2010-12-08 2010-12-08 Sefdinir içeren katı oral dozaj formu.
TR2010/10212 2010-12-08

Publications (2)

Publication Number Publication Date
WO2012078121A2 WO2012078121A2 (fr) 2012-06-14
WO2012078121A3 true WO2012078121A3 (fr) 2012-08-23

Family

ID=45491749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000273 Ceased WO2012078121A2 (fr) 2010-12-08 2011-12-02 Forme posologique orale solide comprenant cefdinir

Country Status (2)

Country Link
TR (1) TR201010212A2 (fr)
WO (1) WO2012078121A2 (fr)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129227A1 (en) * 1996-02-29 2003-07-10 Fujisawa Pharmaceutical Co. Ltd. Beta-lactam antibiotic-containing tablet and production thereof
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20050245738A1 (en) * 2004-05-03 2005-11-03 Lupin Ltd Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
JP2007077123A (ja) * 2005-09-16 2007-03-29 Shiono Chemical Co Ltd 非晶質セフジニル、その製造方法およびこれを含有する経口投与用医薬組成物
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
CN101002745A (zh) * 2005-09-26 2007-07-25 刘凤鸣 头孢地尼的缓释制剂
WO2007086078A2 (fr) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Compositions pharmaceutiques atypiques et processus de preparation correspondant
WO2007129176A2 (fr) * 2006-04-28 2007-11-15 Wockhardt Ltd Traitement amélioré pour traiter des infections bactériennes résistantes
CN101352424A (zh) * 2008-09-16 2009-01-28 天津市中央药业有限公司 头孢地尼分散片及其制备方法
KR20090090467A (ko) * 2008-02-21 2009-08-26 주식회사 중외제약 세프디니르의 용출속도를 개선한 약제학적 조성물
CN101862307A (zh) * 2010-03-19 2010-10-20 杭州奥默医药技术有限公司 硫酸氢头孢地尼钠胶囊及其制备方法
WO2011078820A1 (fr) * 2009-12-25 2011-06-30 Mahmut Bilgic Formulations pharmaceutiques comprenant une céphalosporine de troisième génération et de l'acide clavulanique
WO2011078822A1 (fr) * 2009-12-25 2011-06-30 Mahmut Bilgic Compositions pharmaceutiques comprenant cefdinir comme principe
EP2366379A1 (fr) * 2010-02-25 2011-09-21 Sanovel Ilac Sanayi ve Ticaret A.S. Forme de cefdinir avec taux de dissolution amélioré
WO2011139249A2 (fr) * 2010-05-04 2011-11-10 Mahmut Bilgic Composition pharmaceutique renfermant du cefdinir

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836918B (en) 1982-09-30 1984-05-30 Fujisawa Pharmaceutical Co 7-substituted-3-vinyl-3-cephem compounds and processes for the production of the same

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129227A1 (en) * 1996-02-29 2003-07-10 Fujisawa Pharmaceutical Co. Ltd. Beta-lactam antibiotic-containing tablet and production thereof
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
US20050245738A1 (en) * 2004-05-03 2005-11-03 Lupin Ltd Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof
JP2007077123A (ja) * 2005-09-16 2007-03-29 Shiono Chemical Co Ltd 非晶質セフジニル、その製造方法およびこれを含有する経口投与用医薬組成物
CN101002745A (zh) * 2005-09-26 2007-07-25 刘凤鸣 头孢地尼的缓释制剂
US20070128268A1 (en) * 2005-12-07 2007-06-07 Herwig Jennewein Pharmaceutical compositions comprising an antibiotic
WO2007086078A2 (fr) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Compositions pharmaceutiques atypiques et processus de preparation correspondant
WO2007129176A2 (fr) * 2006-04-28 2007-11-15 Wockhardt Ltd Traitement amélioré pour traiter des infections bactériennes résistantes
KR20090090467A (ko) * 2008-02-21 2009-08-26 주식회사 중외제약 세프디니르의 용출속도를 개선한 약제학적 조성물
CN101352424A (zh) * 2008-09-16 2009-01-28 天津市中央药业有限公司 头孢地尼分散片及其制备方法
WO2011078820A1 (fr) * 2009-12-25 2011-06-30 Mahmut Bilgic Formulations pharmaceutiques comprenant une céphalosporine de troisième génération et de l'acide clavulanique
WO2011078822A1 (fr) * 2009-12-25 2011-06-30 Mahmut Bilgic Compositions pharmaceutiques comprenant cefdinir comme principe
EP2366379A1 (fr) * 2010-02-25 2011-09-21 Sanovel Ilac Sanayi ve Ticaret A.S. Forme de cefdinir avec taux de dissolution amélioré
CN101862307A (zh) * 2010-03-19 2010-10-20 杭州奥默医药技术有限公司 硫酸氢头孢地尼钠胶囊及其制备方法
WO2011139249A2 (fr) * 2010-05-04 2011-11-10 Mahmut Bilgic Composition pharmaceutique renfermant du cefdinir

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200729, Derwent World Patents Index; Class B02, AN 2007-297701, XP002678225, IMAI E; NIWA H: "Non-crystalline amorphous cefdinir for use in oral administration pharmaceutical composition for providing antimicrobial effect against Gram-positive and Gram-negative bacteria in oral cavity, is free from crystalline cefdinir" *
DATABASE WPI Section Ch Week 200821, Derwent World Patents Index; Class A96, AN 2008-C78111, XP002678254, LIU F: "Slow-release preparation of cefdinir in which cefdinir material is added with slow-release framework material according to a stated percentage, then made into solid dispersant with medicine material" *
DATABASE WPI Section Ch Week 200925, Derwent World Patents Index; Class A96, AN 2009-F19584, XP002678228, PANG D; YANG F: "Dispersible tablet comprises specified amount of Cefdinir, and auxiliary materials including disintegrating agent, promoting agent, filler, and other auxiliary materials" *
DATABASE WPI Section Ch Week 201001, Derwent World Patents Index; Class A96, AN 2009-N30656, XP002678226, CHOI M S; HYEON SONG S; SEOK CHOI M; SONG S H: "Pharmaceutical composition for improving dissolution rate of cefdinir, comprises carbonate, solubilizing agent, lubricant, binder, surfactant, coloring agent, buffer agent, diluent, flavoring compound, preserver and filler" *
DATABASE WPI Section Ch Week 201080, Derwent World Patents Index; Class A96, AN 2010-P34926, XP002678227, FANG S; JIE Q; LU M; YE F; YU B; YU M: "Cefdinir sodium bisulfate capsule comprises cefdinir sodium bisulfate, filling agent, disintegrant and lubricant, where filling agent is e.g. glucose and/or lactose, and the disintegrant is e.g. hydroxyethyl cellulose and/or alginic acid" *
VIDHYA PRAKASH ET AL: "Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum beta-lactamases", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 53, no. 3, 1 March 2009 (2009-03-01), pages 1278 - 1280, XP002628190, ISSN: 0066-4804, [retrieved on 20090105], DOI: 10.1128/AAC.01519-08 *

Also Published As

Publication number Publication date
TR201010212A2 (tr) 2012-06-21
WO2012078121A2 (fr) 2012-06-14

Similar Documents

Publication Publication Date Title
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
IL220679A (en) Method of manufacture of solid preparations containing basic active pharmaceutical ingredients and the solid preparations produced by the method
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2011098582A3 (fr) Nouvelles formes de chlorhydrate d'ivabradine
WO2011017502A3 (fr) Formulations comprenant du linaclotide
WO2011157721A3 (fr) Composition pharmaceutique contenant de l'ivabradine
WO2012070062A3 (fr) Nouveau polymorphe de chlorhydrate de nilotinib
WO2012037562A3 (fr) Compositions pharmaceutiques et nutraceutiques d'acide abscisique
WO2011141488A3 (fr) Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2014203275A3 (fr) Procédé amélioré pour la préparation d'apixaban et de ses intermédiaires
WO2010049449A3 (fr) Nouveaux sels de sunitinib
HK1201477A1 (en) Pharmaceutical composition of omeprazole
WO2012074830A3 (fr) Formulation d'acide tranexamique à libération modifiée
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
WO2014068586A3 (fr) Compositions orales solides de tolvaptan
WO2011142731A3 (fr) Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération
WO2010006904A3 (fr) Nouvelles formes cristallines du rabéprazole sodique
WO2011102702A3 (fr) Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan
WO2011139249A3 (fr) Composition pharmaceutique renfermant du cefdinir
WO2011045774A3 (fr) Compositions pharmaceutiques à libération prolongée de palipéridone et leurs procédés de préparation
WO2011095985A3 (fr) Sels de rasagiline et procédés de preparation de ces derniers
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
WO2011138797A3 (fr) Composition pharmaceutique de lansoprazole à action différée se désintégrant par la voie buccale
HU1000299D0 (en) Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11808732

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 13-09-2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11808732

Country of ref document: EP

Kind code of ref document: A2